Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
11 Feb 2016 FDA Grants Breakthrough Therapy Designation for Sacituzumab Govitecan for the Treatment of TNBC Breast cancer - Cancer Immunology and Immunotherapy
10 Feb 2016 Academic Research in Breast Cancer Breast cancer
08 Feb 2016 Exploring the Growing Interest in Drug Repurposing in Oncology Bioethics, legal and economic issues
04 Feb 2016 ESMO Press Release: World Cancer Day 2016 – ESMO and Patient Advocates, Together to Support Research Bioethics, legal and economic issues
04 Feb 2016 ESMO Supports World Cancer Day 2016 Bioethics, legal and economic issues
04 Feb 2016 EMA Adopts a New Indication for Lenalidomide Haematologic malignancies - Anticancer agents & Biologic therapy
03 Feb 2016 Reshaping the Cancer Clinic Personalised medicine
02 Feb 2016 FDA Approves Eribulin Mesylate for the Treatment of Unresectable or Advanced Liposarcoma Sarcomas - Anticancer agents & Biologic therapy
01 Feb 2016 EMA Recommends Granting a Marketing Authorisation for Elotuzumab Haematologic malignancies - Anticancer agents & Biologic therapy
29 Jan 2016 Cancer in China Epidemiology/Etiology/Cancer Prevention
28 Jan 2016 FDA Extends Indications for Ofatumumab in CLL Haematologic malignancies - Anticancer agents & Biologic therapy
27 Jan 2016 Nivolumab plus Ipilimumab Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status Melanoma - Cancer Immunology and Immunotherapy
27 Jan 2016 Annals of Oncology Press Release: Important falls in death rates from leukaemia in Europe predicted for 2016 Haematologic malignancies
07 Jan 2016 New NICE Guidelines to Improve End of Life Care Palliative and supportive care
21 Dec 2015 European Medicines Agency Recommends Two New Indications for Ramucirumab Lung and other thoracic tumours - Gastrointestinal cancers - Anticancer agents & Biologic therapy